Vitrakvi for Adult and Pediatric Solid Tumors

Vitrakvi (larotrectinib, Bayer and Loo Oncology Inc)

Indications: treatment of adult and pediatric patients with solid tumors that:

• have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,

• are metastatic or where surgical resection is likely to result in severe morbidity, and

• have no satisfactory alternative treatments or that have progressed following treatment.

Dosage:

• Adult and Pediatric Patients with Body Surface Area of at Least 1.0 Meter-Squared: 100 mg orally twice daily

• Pediatric Patients with Body Surface Area of Less Than 1.0 Meter-Squared: 100 mg/m2 orally twice daily

Contraindications: None

Click here for more prescribing information